Back to Journal

SM Journal of Nephrology and Kidney Diseases

Times in Range and Nutrition of Individuals on Hemodialysis and Diabetes

[ ISSN : 2576-5450 ]

Abstract Keywords Citation Introduction Discussion Conclusion References
Details

Received: 09-Jul-2024

Accepted: 30-Sep-2024

Published: 30-Sep-2024

Jenny L. Cepeda-Marte1*, Daniela D. Salado-Díaz1,2, Alma M. Hernández-Gómez2, Florangel Guzmán Lora2, Naomi Ruiz2, and Daniela Ortiz2

1Universidad Iberoamericana, Research Hub, Dominican Republic

2Universidad Iberoamericana, Medicine School, Dominican Republic

Corresponding Author:

Jenny L. Cepeda-Marte, Universidad Iberoamericana, Research Hub, Francia Ave. 129. Zip code: 10205. Santo Domingo, Dominican Republic

Abstract

Individuals with diabetes and hemodialysis present a challenge in metabolic control and nutritional adjustment with high nutrient demand. Traditional blood glucose measurement controls, such as self-monitoring, glycated hemoglobin (A1C), and fructosamine, remain uncertain as they do not present the entire picture of glycemic incursions. This review seeks to collect evidence on the efficacy of continuous glucose monitoring, nutritional adjustment, and adequate metabolic control in people with diabetes and hemodialysis. Currently, continuous glucose monitoring plays an essential role in the metabolic control of these individuals, as well as in glycemic variability. No individual standard is exclusive to these conditions concerning the values of the times in range. However, the American Diabetes Association does allow the identification of the average values for high-risk populations and comorbidities associated with diabetes, such as kidney disease. Synchronous metabolic control and nutritional monitoring go hand in hand in people with diabetes and hemodialysis, this being a pillar in comprehensive management to reduce complications and improve the quality of life of these individuals.

Keywords

  • hemodialysis
  • diabetes
  • nutrition
  • Glycemic control.

Citation

Cepeda-Marte JL, Salado-Díaz DD, Hernández-Gómez AM, Lora FG, Ruiz N, et.al, (2024) Times in Range and Nutrition of Individuals on Hemodialysis and Diabetes. J Nephrol Kidney Dis 5(1): 4.

Introduction

With a staggering 537 million people worldwide living with diabetes, it is alarming to note that 30-40% of them also have kidney disease, as per the latest report from the International Diabetes Federation (IDF). This translates to approximately 161-215 million [1]. individuals globally. What’s more, about 10-20% of these individuals are on hemodialysis, making it a significant concern in the healthcare landscape.

The evolution of time ranges in glycemic control for individuals with diabetes has led to a crucial monitoring tool-continuous glucose monitoring [2]. For individuals with diabetes on hemodialysis, this is not just a trend, but a necessity [3]. Continuous glucose monitoring is an indispensable tool, a need that cannot be overlooked for better control of this condition. It has been proven that continuous glucose monitoring is a superior way to improve metabolic control [4]. This tool empowers
individuals undergoing replacement therapy, helping them synchronize many factors to achieve adequate control [5]. These factors include food intake, protein load with the phosphorus ratio, adequacy of lowpotassium foods, and the introduction of complex carbohydrates. They may need to limit sodium in foods and drinks, foods high in phosphorus, the fluid they drink, and even the fluid found in foods. Fluid builds up in the body between hemodialysis treatments [6].

In chronic or advanced kidney disease, there is a decompensation in the patient’s general nutritional status. It is possible to observe alterations in catabolism in some patients, as well as caloric and protein malnutrition. Likewise, this nutritional state is usually accompanied by a general inflammation of the patient, increasing complications in other organs or organ systems of the patient. Therefore, a high morbidity and mortality rate is characteristic of chronic renal patients, more precisely in those who are receiving dialysis. That is why it is necessary to thoroughly optimize the metabolic and nutritional status of patients receiving dialysis [6,7]. This optimization is best achieved through the integration of multidisciplinary nutrition teams, providing comprehensive and individualized care.

In these individuals, protein-calorie malnutrition and inflammation are associated with increased mortality, including a high risk of cardiovascular disease (CVD) [8]. The factors influencing protein-calorie malnutrition are poor dietary intake secondary to associated comorbid conditions and psychosocial factors, particularly lack of adherence to established treatment. Anemia, persistent uremia, glucose intolerance, and altered insulin secretion and degradation influence appetite and the metabolism of these macronutrients [9]. The presence of inflammatory states related to transient vascular access, infections, prolonged hospitalizations, or unscheduled surgical interventions contributes to these alterations not being resolved [10].

This review aims to identify critical aspects in standardizing time in range, treatment adjustment, intake, and achieving or maintaining adequate glycemic control.

Discussion

Individuals undergoing this treatment must adjust their lives to incorporate dialysis treatment sessions into their routine. It can be challenging to adjust the time invert during dialysis sections. There is a need to change work or family life, and some activities and responsibilities have to be given up. Accepting these changes can be difficult for the patient and his or her family. The patient must change what he or she eats and drinks [11].

Traditional tests such as glycosylated hemoglobin and fructosamine do not allow the identification of glycemic variability, which are the peaks and nadirs of glycemia’s incursion [12]. The American Diabetes Association has already introduced continuous glucose monitoring as an essential tool for people on hemodialysis and with diabetes [2]. In addition to the uselessness of A1C in anemia [13] and lack of standardization of fructosamine [14], the MCG with times in range and variability measurement is already part of integral control, providing reassurance and confidence in reducing complications in these individuals [15].

A randomized controlled trial has underscored the crucial role of CGM over A1C and fructosamine in identifying hypoglycemia and hyperglycemia [16,17]. The revelation that hyperglycemia, contrary to common clinical assumptions, is the primary concern for people on hemodialysis is a significant finding [18,19]. This does not, however, diminish the importance of the deleterious effects of hypoglycemia, which can lead to endothelial damage, cardiac rhythm disturbances such as arrhythmias, and sudden death. This underscores the need for effective hypoglycemia management [20-23], a key aspect of the audience’s role in providing care.

The American Diabetes Association’s recommendations are based on individualizing each case, but in particular, for people with diabetes on hemodialysis, a selection of times in range according to individual clinical characteristics, such as hypoglycemia throughout the day, is required. This approach values each patient’s unique needs and ensures more
personalized and effective diabetes management [Figure 1].

Figure 1: Representation of time ranges in fragile/high-risk people with diabetes.

Although specific timeframes are not universally applicable, especially in the context of renal failure, a distinct subset of individuals face unique challenges [25]. These are the individuals on hemodialysis with diabetes [Figure 1]. For them, continuous glucose monitoring is a vital tool [12]. It helps achieve adequate glycemic control and plays a crucial role in
identifying postprandial glycemic incursions and preventing unnoticed hypoglycemia [26]. Reducing long-term complications can significantly enhance their life expectancy [27-29]. Another of the invaluable benefits of continuous glucose monitoring is the postprandial identification of the incursion of glycemia since hyperglycemia is persistent in this population [30]. It is essential to recognize the significant challenges individuals with diabetes and hemodialysis face in their diet, managing the carbohydrates they consume and the content of the micronutrients they contain [31] Table 1. This understanding can help healthcare professionals provide more effective care.

Table 1: Time in range in diabetes [24]:

Individuals with T1&2 DM RECOMMENDED TIME-IN-RANGE
  Recommended level of Blood glucose Required time
  70–180 mg/dL or 3.9–10.0 mmol/L >70% (>16 h 48 min)
Generalized <70 mg/dL or <3.9 mmol/L <4% (<1 h)
  <54 mg/dL or <3 mmol/L <1% (<15 min)
  >180 mg/dL or >10 mmol/L <25% (<6 h)
  >250 mg/dL or >13.9 mmol/L <5% (<1 h, 12 min)
  70–180 mg/dL or 3.9–10.0 mmol/L >50% (>12 h)
OLDER/HIGH RISK/FRAGILE INDIVIDUALS <70 mg/dL or <3.9 mmol/L <1% (<15 min)
  >250 mg/dL or >13.9 mmol/L <10% (<2 h, 24 min)
  63–140 mg/dL or 3.5–7.8 mmol/L >85% (20 h, 24 min)
Pregnancy Type 2/Gestational Diabetes <63 mg/dL or <3.5 mmol/L <4% (<1 h)
mellitus <54 mg/dL or <3 mmol/L <1% (<15 min)
  >140 mg/dL or >7.8 mmol/L <10% (<2 h, 24 min)
  63–140 mg/dL or 3.5–7.8 mmol/L 70% (>16 h 48 min)
PREGNANCY TYPE 1 DM <63 mg/dL or <3.5 mmol/L <4% (<1 h)
  <54 mg/dL or <3 mmol/L <1% (<15 min)
  >140 mg/dL or >7.8 mmol/L <25% (<6 h)

In many cases, the diversity of care in patient selection can lead to malnutrition due to misinformation about intake and the fear of worsening health. All hemodialysis units must constantly screen for nutritional risk, as this is vital for the proper management of the nutritional plan. This commitment to comprehensive care is essential for the well-being of our patients. Currently, different methods have been proposed to assess the nutritional status of patients on hemodialysis, such as modified subjective global assessment (MSGA) and the malnutrition and inflammation score (MIS), which evaluate altered parameters in these patients [32]. The Subjective Global Assessment (SGA) is a tool that identifies malnutrition by combining subjective parameters of nutritional assessment and clinical history, considering weight loss, muscle mass loss, and daily food intake [33]. Regarding the analytical parameter, the measurement of serum albumin in correlation with the C-reactive protein (CRP) value is a marker of nutritional status, being directly proportional to protein intake, and is included by the different consensuses as part of the diagnosis of protein deficiency [34]. Other tools available in the evaluation of nutritional status are the determination of total body composition through bioimpedance, this procedure being capable of measuring the hydration status, determining dry weight in dialysis, and therefore providing information on nutritional status through measuring lean mass and fat mass [7].

It is relevant to highlight that the nutritional status of hemodialysis patients is crucial for their health since poor nutrition influences the decrease in mass and strength in skeletal muscle. This affects their quality of life, both physically and emotionally, raising mortality rates [35]. Complementing hemodialysis with specialists in nutrition and exercise can achieve Functional, satisfactory results in improving patients’ nutritional status and physical strength on chronic hemodialysis. The
“Subjective Global Assessment” (SGA) is essential for evaluating a patient’s nutritional status. It predicts future nutritional complications and helps determine whether the patient will improve or worsen [32]. 

Another tool is bioimpedance, which consists of a low-cost, noninvasive process using electrodes that allow the calculation and analysis of body composition; due to this, bioimpedance is considered helpful in assessing the patient’s hydration status on hemodialysis. Its periodic performance, monthly or quarterly, or more frequently if the patient is unstable or requires weight adjustment, can help determine whether we are close to the patient’s dry weight, which is the weight after
hemodialysis [7].

On the other hand, subjective global assessment is a tool that uses structured clinical parameters to diagnose malnutrition. Its objective is to identify patients likely to benefit from nutritional intervention and, therefore, to identify people in whom inadequate nutrient intake or absorption explains the characteristics of malnutrition [36]. Since nutritional status affects health-related quality of life and that decreased health-related quality of life in hemodialysis patients is associated with mortality, complications, and lower treatment compliance, the use of subjective global assessment to measure nutritional status can be a tool to help identify dialysis patients with a lower health-related quality of life [37]. Highlighting the fact that there is a gap between a renal dietitian and a health professional working in a dialysis unit since there is a greater level of detail with the renal dietitian when calculating the amounts and proportions of nutritional requirements and metabolic adjustment.

Conclusion

The integration of continuous glucose monitoring in people with diabetes and on hemodialysis is the pillar of metabolic control in these individuals. It avoids future complications and improves quality and life expectancy. 

Advice from a renal dietitian is essential when it comes to nutrition for hemodialysis patients, as the amount of protein, calories, and supplements will be adjusted depending on the patient’s requirements. The specialist will plan the appropriate amounts of protein to maintain the patient’s strength and lifestyle.

Integrating multidisciplinary nutrition teams in these individuals guarantees an adequate adjustment to avoid malnutrition and metabolic decompensation and a safe, individualized, and sufficient food intake.

References

1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et.al IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119.
2. Committee ADAPP, ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, et al. 7. Diabetes Technology: Standards of Care in Diabetes—2024. Diabetes Care. 2024; 47: 126-144.
3. Chantrel F, Sissoko H, Képénékian L, Smagala A, Meyer L, Imhoff O, et al. Influence of dialysis on the glucose profile in patients with diabetes: Usefulness of continuous glucose monitoring. Horm Metab Res. 2014; 46: 810-813.
4. Joubert M, Fourmy C, Henri P, Ficheux M, Lobbedez T, Reznik Y. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: The DIALYDIAB pilot study. Diabetes Res Clin Pract [Internet]. Full length article 2015; 107: 348–54.
5. Jakubowska Z, Malyszko J. Continuous glucose monitoring in people with diabetes and end-stage kidney disease—review of association studies and Evidence-Based discussion. J Nephrol. 2024; 37: 267-279.
6. Vijaya K, Aruna M, Narayana Rao SVL, Mohan P. Dietary counseling by renal dietician improves the nutritional status of hemodialysis patients. Indian J Nephrol. 2019; 29: 179-185.
7. Elvira-Carrascal S, Rota-Musoll L, Bou-Folgarolas J, Homs-del Valle M, Puigoriol-Juvanteny E, Chirveches-Pérez E. Impacto de una intervención educativa nutricional para pacientes en hemodiálisis medido mediante la escala Malnutrición Inflamación y la bioimpedancia eléctrica. Enfermería Nefrológica. 2022; 25.
8. Núñez VI. Evaluación del estado nutricional en pacientes en hemodiálisis del Hospital San Martín de La Plata a través de dos herramientas validadas. 2018.
9. Sellarésa V.L, Rodríguez D.L. Alteraciones Nutricionales en la Enfermedad Renal Crónica (ERC) - Nefrología al día. 2659-2606.
10. Hevilla F, Padial M, Blanca M, Barril G, Jiménez-Salcedo T, Ramirez- Ortiz M, et al. Effect on nutritional status and biomarkers of inflammation and oxidation of an oral nutritional supplement (with or without probiotics) in malnourished hemodialysis patients. A multicenter randomized clinical trial “Renacare Trial.” Front Nutr. 2023; 10: 1107869.
11. Hendriks FK, Kooman JP, van Loon LJC. Dietary protein interventions to improve nutritional status in end-stage renal disease patients undergoing hemodialysis. Curr Opin Clin Nutr Metab Care. 2021; 24: 79-87.
12. Saboo B, Kesavadev J, Shankar A, Krishna MB, Sheth S, Patel V, et al. Time-in-range as a target in type 2 diabetes: An urgent need. Heliyon. 2021; 7: e05967.
13. Gómez Medina A, González CA, Muñoz OM, Gómez Y, Jaramillo PE, Henao D, et al. HbA1c overestimates the glucose management indicator: a pilot study in patients with diabetes, chronic kidney disease not on dialysis, and anemia using isCGM. Ther Adv Endocrinol Metab. 2024; 15.
14. Kaminski CY, Galindo RJ, Navarrete JE, Zabala Z, Moazzami B, Gerges A, et al. Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes. Diabetes Care. 2024; 47: 267–271.
15. TOTOMIROVA T, ARNAUDOVA M, DASKALOVA I. 900-P: HbA1c Is an Insufficient Glucose Control Assessment Tool in Type 1 and Type 2 Treated with Insulin. Diabetes 69. 2020; 900-P.
16. Tylee TS, Trence DL. Glycemic Variability: Looking Beyond the A1C. Diabetes Spectrum. 2012; 25: 149-153.
17. Ikeda M, Shimazawa R. Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus. J Gen Fam Med. 2019; 20: 129-138.
18. Ahmad I, Zelnick LR, Batacchi Z, Robinson N, Dighe A, Manski- Nankervis JAE, et al. Hypoglycemia in people with type 2 diabetes and CKD. Clinical J Am Soc Nephrol. 2019; 14: 844-853.
19. Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. Endocr Rev . 2020; 41: 756–774.
20. Tian J, Ohkuma T, Cooper M, Harrap S, Mancia G, Poulter N, et al. Effects of Intensive glycemic control on clinical outcomes among patients with type 2 diabetes with different levels of cardiovascular risk and hemoglobin A1c in the ADVANCE trial. Diabetes Care. 2020; 43: 1293-1299.

21. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-39.
22. Gerstein H C, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545–59.
23. Nathan DM. Some answers, more controversy, from United Kingdom Prospective Diabetes Study. Lancet. 1998; 352: 832–3.
24. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017; 40: 1631-1640.
25. Brøsen JMB, Bomholt T, Borg R, Persson F, Pedersen-Bjergaard U. Hyperglycaemia in people with diabetes and chronic kidney disease. Ugeskr Laeger. 2024; 186: V01240051.
26. Lu J, Ma X, Zhang L, Mo Y, Lu W, Zhu W, et al. Glycemic variability modifies the relationship between time in range and hemoglobin A1c estimated from continuous glucose monitoring: A preliminary study. Diabetes Res Clin Pract. 2020; 161.
27. Guo Q, Zang P, Xu S, Song W, Zhang Z, Liu C, et al. Time in Range, as a Novel Metric of Glycemic Control, Is Reversely Associated with Presence of Diabetic Cardiovascular Autonomic Neuropathy Independent of HbA1c in Chinese Type 2 Diabetes. J Diabetes Res. 2020; 2020: 5817074.
28. Mayeda L, Katz R, Ahmad I, Bansal N, Batacchi Z, Hirsch IB, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res & Care. 2020; 8: e000991.
29. Lu J, Ma X, Zhou J, Zhang L, Mo Y, Ying L, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 2018; 41: 2370–2376.
30. Lee S, Lee S, Kim KM, Shin JH. Usefulness of continuous glucose monitoring of blood glucose control in patients with diabetes undergoing hemodialysis: A pilot study. Front Med. 2023; 10: 1145470.
31. Kistler BM, Moore LW, Benner D, Biruete A, Boaz M, Brunori G, et al. The International Society of Renal Nutrition and Metabolism Commentary on the National Kidney Foundation and Academy of Nutrition and Dietetics KDOQI Clinical Practice Guideline for Nutrition in Chronic Kidney Disease. J Ren Nutr. 2021; 31: 116-120.
32. Sohrabi Z, Kohansal A, Mirzahosseini H, Naghibi M, Zare M, Haghighat N, et al. Comparison of the Nutritional Status Assessment Methods for Hemodialysis Patients. Clin Nutr Res. 2021; 10: 219.-229.
33. Blagg CR. Importance of nutrition in dialysis patients. Am J Kidney Dis. 1991; 17: 458-461.
34. Harty JC, Boulton H, Curwell J, Heelis N, Uttley L, Yenning MC, et al. The normalized protein catabolic rate is a flawed marker of nutrition in CAPD patients. Kidney Int. 1994; 45:103-109.
35. Sahathevan S, Khor BH, Ng HM, Gafor AHA, Daud ZAM, Mafra D, et al. Understanding Development of Malnutrition in Hemodialysis Patients: A Narrative Review. Nutrients. 2020; 12: 3147.
36. Duerksen DR, Laporte M, Jeejeebhoy K. Evaluation of Nutrition Status Using the Subjective Global Assessment: Malnutrition, Cachexia, and Sarcopenia. Nutr Clin Pract. 2021; 36: 942–956.
37. Vero LM, Byham-Gray L, Parrott JS, Steiber AL. Use of the Subjective Global Assessment to Predict Health-Related Quality of Life in Chronic Kidney Disease Stage 5 Patients on Maintenance Hemodialysis. J Ren Nutr. 2013; 23: 141-147.

Other Articles

Article Image 1

High-Dose Statin Associated with Rhabdomyolysis, Acute Kidney Injury, Cholestatic Liver Injury, and Thrombocytopenia

Introduction: Statins are the drugs of choice to reduce cholesterol and the incidence of cardiovascular events. Although rare, the side effects of these drugs may be severe (especially when given in the high doses recommended by the cardiologists), including: muscle damage, renal and liver injury and compromised function, and polyneuropathy.

Case Report: We report a case of statin-induced rhabdomyolysis, acute kidney and liver failure and thrombocytopenia that developed in a 76-year-old man, who was referred to our department because of severe generalized myalgia and muscle weakness, extreme fatigue, loss of appetite, dark brown urine. Following an acute myocardial infarction 8 months previously he was put on atorvastatin 80 mg once daily. Laboratory evaluation at presentation revealed much increased levels of muscle enzymes, aminotransferases, total and conjugated bilirubin, and nitrogenous waste products, and low platelets. A diagnosis of acute renal and liver failure secondary to the long-term intensive statin therapy was made. Atorvastatin was discontinued and forced alkaline diuresis was started. After five days of oliguria and slight but persistent increase in creatinine levels dialysis was initiated, but discontinued after 4 sessions, once urine output increased. At discharge the patient’s serum creatine kinase level was in the normal range, creatinine was significantly decreased the thrombocyte count was better, aminotransferase were much lower but not completely normalized, but the bilirubin remained at the same level. The patient was discharged and instructed to avoid any potentially nephrotoxic and hepatotoxic drugs until next outpatient evaluation.

Conclusions: Our case report is meant to raise concerns about prescribing high dose statins. Unfortunately the prescribing cardiologists may be insufficiently aware of the potential for severe adverse effects as these come to the attention of clinicians from different specialities, especially nephrologists.

Dorin Dragos1,2, Diana Pruteanu2 and Rodica Constantin2


Article Image 1

Infections in Pediatric Dialysis Patients in Mubarak Al-Kabeer Hospital, Kuwait: 10 Year

Objective: As the incidence of End Stage Renal Disease (ESRD) worldwide has increased, so has the need for performing Hemodialysis (HD) and Peritoneal Dialysis (PD). We sought to identify risk factors and measure the rate of infections in pediatric patients undergoing dialysis.

Design: A retrospective study

Setting: Single pediatric dialysis center in Kuwait from July 2003-July 2013

Subjects: Pediatric patients undergoing PD or HD

Interventions: Follow up of risk factors and rate of infections incidents

Main outcome measures: Risk factors, incidence rate of infections and microbiological profile of organisms causing dialysis-related infections were determined in HD or PD patients.

Results: A total of 91 patients underwent HD and 63 patients underwent PD. The episodes of infection were documented in 13 patients in each of the two groups. Our rates of infection were found to be one peritonitis episode per 20 patient-months in PD group and 0.41 infection episodes per patient-year in HD group. The commonest organisms isolated in PD-related infections were Pseudomonas aeruginosa and CoagulaseNegative Staphylococci (CNST) whereas in HD-related infections CNST was the leading organism. Among the risk factors in both groups, personal hygiene was the most significant with a P-value of

Conclusion: Our infection rates were consistent with international reports and consistent with others in proving poor personal hygiene as a significant risk factor for infection in patients undergoing renal dialysis.

Wadha Alfouzan¹˒²*, Faisal Alkandari³, Ayman Yosri³, Fawaz Azizieh⁴, Haya Al Tawalah⁵ and Dhar R²


Article Image 1

Evaluating the Kidney Stones; are the Volume and Size Equal in One or Two Dimensions? Accustomed Inaccuracy

Urinary lithiasis is a common disease, prevalence rates vary from 1% to 20%, according to gender, dietary, ethnic, the geographical, and genetic factors.

Musab Ilgi*, Kaya Horasanli and Sinan Levent Kirecci


Article Image 1

Biochemical and Histological Evaluation of Kidney Function in Rats after a Single Administration of Cyclophosphamide and Ifosfamide

Background: Cyclophosphamide (CP) and Ifosfamide (IF) are widely used cytotoxic agents. Both CP and IF exert some characteristic adverse drug reactions including kidney damage taking various clinical forms, depending on the applied dose or administration route. The aim of our study was to estimate kidney function using selected, classical biochemical parameters as well as analyzing the urinary concentration and excretion of a modern “kidney troponin” - neutrophil gelatinase-associated lipocalin-1 (NGAL-1) in rats after administration of a single CP or IF dose.

Methods: 30 rats were divided into three groups (n=10 each; half males and females): group 1 - control (rats receiving i.p. saline solution); groups 2 and 3 – rats intraperitoneally treated with a single CP or IF dose of 150 mg/kg b.w., respectively. Following saline/CP/IF administration, animals were housed in single metabolic cages, to assess 24-hour diuresis and to obtain urinary samples for further laboratory assays. Finally, blood samples were collected and rats were sacrificed to perform autopsy with cystectomy and nephrectomy with subsequent histopathological analysis. Standard parameters of kidney function were assayed either in blood or in urine with an additional assessment of the urine NGAL-1 level.

Results: Single administration of both CP and IF resulted in decreased pH of urine and proteinuria accompanied by an increased 24-hour urinary NGAL-1 excretion. Moreover, CP-treated rats demonstrated polyuria. Concentrations and 24-hour excretion of most classical, low-weight parameters were not different in both CP- and IF-treated rats compared to values observed in control animals.

The histopathological analysis in CP/IF treated animals revealed presence of cystic inflammatory lesions and a normal kidney structure, with the exception of a mild to moderate congestive hyperemia.

Conclusion: A single administration of CP and IF caused a functional kidney tubulopathy in study rats manifested by marked proteinuria with increased 24-hour NGAL-1 urinary excretion.

Łukasz Dobrek*, Agnieszka Baranowska, Beata Skowron and Piotr Thor


Article Image 1

Serum Glycoprotein Chondrex (YKL-40) and High Sensitivity C- Reactive Protein (hscrp) in Type 2 Diabetic Patients in Relation to Cardiovascular Complications

In Type 2 diabetes, C-Reactive Protein (CRP) as an inflammatory marker may be elevated. The glycoprotein Chondrex or YKL-40 is over expressed in many inflammatory conditions. The aim is to study serum hsCRP and YKL-40 in Type 2 diabetic patients in relation to cardiovascular complications.

Methods: Eighty subjects were divided into 3 groups: GROUP 1:16 apparently healthy controls, GROUP 2:16 patients suffering from Type 2 DM without cardiovascular complications and GROUP 3: 48 patients suffering from Type 2 DM with cardiovascular complications. Subjects with acute or chronic inflammation, autoimmune disease or malignancy were excluded. Electrocardiography, Carotid Intima Thikness, Fundus Examination, laboratory investigations: (Complete urine analysis, urinary albumin, Creatinine and calculation of urinary albumin to creatinine ratio, fasting and postprandial glucose, glycated hemoglobin, Creatinine and uric acid, lipid profile, glomerular filtration rate, CRP and YKL-40) were done to all subjects.

Results: High sensitivity CRP levels were significantly elevated in the diabetic group with cardiovascular complications when compared to the diabetic group without cardiovascular complications (p=0.024). YKL-40 was significantly higher in patients with type 2 diabetes mellitus than controls (p=0.017) and cardiovascular complications (p<0.001) contributed to its greater elevation.YKL-40 was positively correlated with triglycerides, systolic and mean blood pressure in the group of diabetic patients without cardiovascular complications and with duration of diabetes and urinary albumin to creatinine ratio in the group with cardiovascular complications. By drawing receiver operating characteristic (ROC) curve between diabetic patients without and with cardiovascular complications the AUC for hsCRP was (0.676, p=0.036) and for YKL-40 was (0.743, p=0.004). By studying the diagnostic performance, YKL-40 had a better specificity and positive predictive value than hsCRP.

Conclusion: YKL-40 has a better specificity and positive predictive value than hsCRP in discriminating between diabetic patients with cardiovascular complications from those without cardiovascular complications.

El-Attar HA¹*, El-Deeb MM¹ and El-Ghlied LA²


Article Image 1

Is There An Association Between Angiotensin II Type 1 Receptor A1166C Gene Polymorphism and Renal Scarring Susceptibility?

Relationship between Angiotensin II Type 1 Receptor (AT1R) A1166C gene polymorphism and renal scarring risk is still controversial. This meta-analysis was performed to evaluate the association of AT1R A1166C gene polymorphism and renal scarring risk susceptibility. A predefined literature search and selection of eligible relevant studies were performed to collect data from electronic databases of PubMed, Embase and Cochrane Library. Three literatures were identified and included for the analysis of the relationship between AT1R A1166C gene polymorphism and renal scarring risk. We found that AT1R A1166C gene polymorphism was not associated with renal scarring susceptibility using the comparison of patients with scarring vs patients without scarring (C: OR=1.33, 95%CI: 0.83-2.13, P=0.23; CC: OR=1.71, 95%CI: 0.22-13.56, P=0.61; AA: OR=0.69, 95%CI: 0.39-1.21, P=0.20). Furthermore, AT1R A1166C gene polymorphism was also not associated with renal scarring risk using the comparison of patients with scarring vs healthy control. In conclusion, AT1R A1166C gene polymorphism was not associated with renal scarring risk susceptibility. However, more studies should be performed in the future.

Tianbiao Zhou*#, Weiji Xie#, Zhijun Lin# and Zhensheng Yang


Article Image 1

Evaluation of Antidiabetic Plants used by Tribes of Telangana State on Diabetic Complications like Neuropathy, Nephropathy and Cardiomyopathy in Rats

Background: India is “diabetes capital of the world”. Diabetes Atlas 2006 published by International Diabetes Federation, India currently around 40.9 million is expected to rise to 69.9 million by 2025 unless urgent preventive steps are taken. Over the past 30 yr, the status of diabetes has changed from being considered as a mild disorder to major causes of morbidity and mortality.

Methods: Rats treated with Alloxan (150 mg/kg) i.p. results diabetic rats given ethanol extract of Senna auriculata leaf, Syzygium cumini (L.) Skeels seeds and Syzygium cumini (L.) Skeels seeds (150 mg/kg) p.o., respectively for 42 days. Biochemical parameters of diabetic neuropathy, nephropathy and cardiomyopathy and histopathology of sciatic nerve, kidney and heart was done at the end of study.

Results: In Diabetic Group found Blood Glucose Level (BGL) (84.42±6.384 to 369.36±7.784mg/dl); Muscle Grip Strength (MGS) (59.32±1.052 to 13.52±0.883seconds); Thermal Pain Response (TPR) (5.55±0.621 to 13.67±1.164seconds). blood protein (7.48±0.051 to 25.18±0.046mg/dl); urine protein (0.692±0.061 to 2.68±0.056mg/dl); blood albumin (1.94±0.043 to 0.248±0.007mg/dl); urine albumin (0.082±0.009 to 2.68±0.056mg/dl); blood myoglobin (0.042±0.00274 to 0.056±0.00207ng/dl); urine myoglobin (0.0048±0.00142 to 0.0098±0.00107mg/dl); Blood Urea Nitrogen (BUN) (23.04±1.093 to 124.81±1.238 mg/dl); Serum Creatinine (84.06±6.723 to 218.56±7.586 (µMol/dl). Etholic extract of Senna auriculata leaf, Phyllanthus emblica.L. fruits and Syzygium cumini (L.) Skeels seeds & combination treated groups found BGL124.42±7.042, 112.07±6.942, 126.25±7.051 & 98.83±6.932mg/dl; MGS 49.06±0.962, 52.05±1.247, 54.06±1.268 & 56.79±1.125 seconds; TPR 6.54±0.841, 7.38±0.802, 6.45±1.062 & 6.14±0.837 seconds; blood protein 7.98±0.039, 8.02±0.053, 8.06±0.039 & 7.48±0.045mg/dl; urine protein 1.22±0.058, 0.94±0.049, 0.96±0.056 & 0.82±0.062mg/dl; blood albumin 1.64±0.033, 1.82±0.036, 1.87±0.044 & 1.96±0.039mg/dl; urine albumin 0.122±0.008, 0.098±0.007, 0.132±0.009 & 0.108±0.011mg/dl; blood myoglobin 0.045±0.00189, 0.036±0.00177, 0.041±0.00223 & 0.043±0.00175ng/dl; urine myoglobin 0.0042±0.00129, 0.0052±0.00119, 0.0064±0.00126 & 0.0036±0.00125mg/dl; BUN 35.81±1.186, 36.06±1.123, 34.53±1.177 & 29.03±1.229mg/dl; Serum Creatinine 98.42±5.526, 99.73±6.064, 101.97±6.052 & 94.83±6.678µMol/dl.

Conclusion: Ethanol extract of Senna auriculata leaf, Phyllanthus emblica L. fruit and Syzygium cumini (L.) Skeels seeds (150mg/kg) and its combination normalizes biochemical parameters & Morphological changes in sciatic nerve, myocardium & kidney and improvement of the general behavioral parameters. Combination was found to be more effective in these diabetic complications.

Syed Ahmed Hussain and Ashish Kumar Sharma*


Article Image 1

Uric Acid, Metabolic Risk Factors, and Chronic Kidney Disease: Clinical Investigation in a Female Elderly Occupational Population in Taipei, Taiwan

Purpose: To explore the prevalence and associated factors for Chronic Kidney Disease (CKD) among female elderly fishing and agricultural population in Taipei, Taiwan.

Methods: Females (n=1,606) aged 65 years and over voluntarily admitted to a teaching hospital for a physical check-up were collected in 2010.

Results: The prevalence of CKD was 8.2%. Age, hyperuricemia, and hyperglycemia were statistical significantly related to CKD. The sensitivity and specificity of serum uric acid and fasting blood glucose concentration as a marker of CKD were estimated 76.5%, 70.9% and 51.5%, 53.5%, respectively.

Conclusion: Hyperuricemia and hyperglycemia independently affect the prevalent CKD in this sub-population.

Ya-Ting Liang¹, Hsi-Che Shen²˒³˒⁴, Yi-Chun Hu²˒³˒⁵, Yu-Fen Chen⁶˒⁷˒⁸ and Tao-Hsin Tung⁹˒¹⁰˒¹¹*


Article Image 1

Pseudohypercreatininemia after Sustanon Injection

The drugs used in the treatment of certain diseases may give impression of impaired renal function. These drugs cause a false high serum creatinine level. Laboratory findings other than serum creatinine and hypertriglyceridemia were normal. We presented a 28-year-old male with a high serum creatinine level, who was referred for consideration of urgent renal replacement therapy. The results of the investigations revealed that the result was the falsely-elevated serum creatinine due to the sustenance injection.

Can Hüzmeli¹, Mustafa Sağlam¹, Bariş Döner¹, Serkan Çağlar² and Özkan Güngör³


Article Image 1

Peripheral Arterial Disease Holding Central Stage in Chronic Kidney Disease (Kdoqi Stage 3-5): Prevalence and Related Risk Factors - Experience from Kashmir Valley Tertiary Care Centre

Patients with CKD are highly predisposed for developing accelerated atherosclerosis. These patients have non-traditional risk factors such inflammation, malnutrition and increased oxidative stress that enhance and accelerate atherosclerosis in addition to traditional risk factors. Although relation between cardiovascular and cerebrovascular diseases with CKD is well established, studies are suggesting about association of Peripheral Arterial Disease (PAD) with CKD. PAD is associated with increased morbidity and mortality in patients of CKD.

This study is rendezvous to look for PAD and related risk factors in patients of CKD having eGFR less than 60 ml/ min/ 1.73 m2 (MDRDS) and not on RRT.

Two hundred ten subjects with CKD attending department of nephrology at tertiary care institute in valley were included in study. Out of 210 subjects selected, 30 were having PAD that constituted 14% of study population. IC was seen in 25 (11.9%) of 210 subjects. Out of PAD patients 16 (53.3%) were having history of IC and 14 (46.7%) were asymptomatic. As reported in literature, prevalence of peripheral arterial disease in CKD patients not on dialysis ranged from 7% to 32% in previous cases. This study will sensitize us to plan more effective screening, preventive and management strategies. This will go long way to decrease morbidity and mortality in patients.

Mohamad Muzzafer Mir*, Mohamad Saleem Najar, Bipin Kumar Sharma, Mangit Singh, Ursilla Taranum Mir and Majid Khalil Rather